Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific internal transaction rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of Ordinary share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on December 23, 2011.
- Price: The transaction price was $45.65 per ADR.
- Parties Involved: The transaction involved Director Dr. M M Slaoui and Connected Person Dr. K Slaoui.
- Volume: The transaction involved 3 ADRs.
- Context: This was a re-valuation event within a retirement plan, not a direct market purchase or sale by the individuals.